Private Advisor Group, LLC Vertex Pharmaceuticals Inc Transaction History

Private Advisor Group, LLC

$15.6 Billion
Q3 2024

A detailed history of Private Advisor Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Private Advisor Group, LLC holds 7,244 shares of VRTX stock, worth $3.37 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

7,244

Previous 8,221 11.88%

Holding current value

$3.37 Million

Previous $3.85 Million 12.56%

% of portfolio

0.02%

Previous 0.03%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$460.0 - $505.78 $449,420 - $494,147	-977 Reduced 11.88%	7,244 $3.37 Million
Q2 2024 Aug 05, 2024	BUY	$392.81 - $485.53 $95,452 - $117,983	243 Added 3.05%	8,221 $3.85 Million
Q1 2024 Apr 30, 2024	SELL	$407.69 - $446.08 $955,217 - $1.05 Million	-2,343 Reduced 22.7%	7,978 $3.33 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $171,500 - $205,340	500 Added 5.09%	10,321 $4.2 Million
Q3 2023 Nov 02, 2023	SELL	$338.18 - $362.46 $978,692 - $1.05 Million	-2,894 Reduced 22.76%	9,821 $3.42 Million
Q2 2023 Aug 09, 2023	BUY	$314.42 - $351.91 $2.07 Million - $2.32 Million	6,591 Added 107.63%	12,715 $4.47 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $337,893 - $385,458	-1,193 Reduced 16.3%	6,124 $1.93 Million
Q4 2022 Jan 18, 2023	BUY	$285.76 - $321.48 $433,497 - $487,685	1,517 Added 26.16%	7,317 $0
Q3 2022 Oct 14, 2022	SELL	$273.83 - $305.53 $7.11 Million - $7.93 Million	-25,971 Reduced 81.74%	5,800 $1.68 Million
Q2 2022 Jul 13, 2022	BUY	$234.96 - $292.55 $506,338 - $630,445	2,155 Added 7.28%	31,771 $8.95 Million
Q1 2022 May 12, 2022	SELL	$221.42 - $260.97 $301,795 - $355,702	-1,363 Reduced 4.4%	29,616 $7.73 Million
Q4 2021 Feb 10, 2022	SELL	$177.01 - $223.45 $159,840 - $201,775	-903 Reduced 2.83%	30,979 $6.8 Million
Q3 2021 Oct 14, 2021	BUY	$181.39 - $202.99 $717,397 - $802,825	3,955 Added 14.16%	31,882 $5.78 Million
Q2 2021 Aug 12, 2021	BUY	$187.49 - $221.1 $3.07 Million - $3.62 Million	16,382 Added 141.9%	27,927 $5.63 Million
Q1 2021 Apr 22, 2021	BUY	$207.02 - $241.31 $287,550 - $335,179	1,389 Added 13.68%	11,545 $2.48 Million
Q4 2020 Apr 01, 2021	BUY	$207.01 - $276.09 $240,545 - $320,816	1,162 Added 12.92%	10,156 $2.4 Million
Q3 2020 Nov 02, 2020	BUY	$255.65 - $303.1 $459,914 - $545,276	1,799 Added 25.0%	8,994 $2.51 Million
Q2 2020 Aug 17, 2020	BUY	$225.48 - $295.8 $505,977 - $663,775	2,244 Added 45.32%	7,195 $2.09 Million
Q1 2020 May 12, 2020	BUY	$199.77 - $247.81 $52,339 - $64,926	262 Added 5.59%	4,951 $1.18 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $153,373 - $205,997	-920 Reduced 16.4%	4,689 $1.03 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $298,881 - $336,387	1,798 Added 47.18%	5,609 $996,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $128,066 - $148,107	-778 Reduced 16.95%	3,811 $691,000
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $78,754 - $93,650	481 Added 11.71%	4,589 $845,000
Q4 2018 Feb 11, 2019	SELL	$151.91 - $192.21 $160,113 - $202,589	-1,054 Reduced 20.42%	4,108 $681,000
Q3 2018 Nov 01, 2018	BUY	$167.73 - $192.74 $281,786 - $323,803	1,680 Added 48.25%	5,162 $995,000
Q2 2018 Aug 09, 2018	BUY	$145.72 - $169.96 $150,965 - $176,078	1,036 Added 42.35%	3,482 $591,000
Q1 2018 May 09, 2018	SELL	$151.6 - $177.13 $233,312 - $272,603	-1,539 Reduced 38.62%	2,446 $399,000
Q4 2017 Feb 07, 2018	SELL	$137.28 - $155.55 $267,421 - $303,011	-1,948 Reduced 32.83%	3,985 $621,000
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $70,509 - $77,226	476 Added 8.72%	5,933 $921,000
Q2 2017 Aug 10, 2017	BUY	N/A	5,457	5,457 $702,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.

Account

Private Advisor Group, LLC Vertex Pharmaceuticals Inc Transaction History